mmpc-logo mmpc-logo
twitter-logo    bluesky-logo
| Create Account | login
Publication
Minimal dosing of leukocyte targeting TRAIL decreases triple-negative breast
cancer metastasis following tumor resection.
Authors Jyotsana N, Zhang Z, Himmel LE, Yu F, King MR
Submitted By Submitted Externally on 12/11/2019
Status Published
Journal Science advances
Year 2019
Date Published 7/1/2019
Volume : Pages 5 : eaaw4197
PubMed Reference 31355333
Abstract Surgical removal of the primary tumor is a common practice in breast cancer
treatment. However, postsurgical metastasis poses an immense setback in cancer
therapy. Considering that 90% of cancer-related deaths are due to metastasis,
antimetastatic therapeutic strategies that can target disseminating tumor cells
in the circulation before they can form secondary tumors hold preclinical and
clinical potential for cancer patients. Our current work uses a liposomal
formulation functionalized with the adhesion receptor E-selectin and the
apoptosis-inducing ligand TNF (tumor necrosis factor)-related apoptosis-inducing
ligand (TRAIL) to reduce metastasis following tumor resection in an aggressive
triple-negative breast cancer (TNBC) mouse model. We demonstrate that minimal
administration of E-selectin-TRAIL liposomes can target metastasis in a TNBC
model, with primary tumor resection to mimic clinical settings. Our study
indicates that TRAIL liposomes, alone or in combination with existing clinically
approved therapies, may neutralize distant metastasis of a broad range of tumor
types systemically.




Menu

Home
Contact
About MMPC
Animal Husbandry
Tests Data
Search Data
Analysis
Clients
MMPC Centers

Newsletter

Interested in receiving MMPC News?
twitter-logo Mouse Phenotyping
@NationalMMPC



2017 National MMPC. All Rights Reserved.